Drugs / CRELOSIDENIB
CRELOSIDENIB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05205447 | Jan → Apr 2022 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT06181084 | Oct 2021 → Apr 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06181045 | Feb → Aug 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04603001 | Nov 2020 → Jul 2023 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04521686 | Oct 2020 → Jul 2023 overdue | cholangiocarcinoma, chondrosarcoma, glioma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRELOSIDENIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6000618 ↗ |
| Known as | LSN-3856920 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6000618 ↗ |
| Known as | LY3410738 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205447 ↗ |
| Action | Inhibit | “an oral, covalent isocitrate dehydrogenase (IDH) inhibitor” NCT04603001 ↗ |
| Modality | Small molecule | — CHEMBL6000618 ↗ |
| Route | Oral | “Oral LY3410738” NCT04521686 ↗ |